Significant reduction of red blood cell transfusion requirements by changing from a double-unit to a single-unit transfusion policy in patients receiving intensive chemotherapy or stem cell transplantation

Abstract

BackgroundTraditionally, single-unit red blood cell transfusions were believed to be insufficient to treat anemia, but recent data suggest that they may lead to a safe reduction of transfusion requirements. We tested this hypothesis by changing from a double-to a single-unit red blood cell transfusion policy. Design and MethodsWe performed a retrospective cohort study in patients with hematologic malignancies receiving intensive chemotherapy or hematopoietic stem cell transplantation. The major end-points were the reduction in the total number of red blood cell units per therapy cycle and per day of aplasia. The study comprised 139 patients who received 272 therapy cycles. Overall 2212 red blood cell units were administered in 1548 transfusions. ResultsDuring the periods of the double-and single-unit policies, one red blood cell unit was transfused in 25% and 84% of the cases and the median number of red blood cell units per transfusion was two and one, respectively. Single-unit transfusion led to a 25% reduction of red blood cell usage per therapy cycle and 24% per aplasia day, but was not associated with a higher outpatient transfusion frequency. In multivariate analysis, single-unit transfusion resulted in a reduction of 2.7 red blood cell units per treatment cycle (P=0.001). The pre-transfusion hemoglobin levels were lower during the single-unit period (median 61 g/L versus 64 g/L) and more transfusions were administered to patients with hemoglobin values of 60 gl/L or less (47% versus 26%). There was no evidence of more severe bleeding or more platelet transfusions during the single-unit period and the overall survival was similar in both cohorts. ConclusionsImplementing a single-unit transfusion policy saves 25% of red blood cell units and, thereby, reduces the risks associated with allogeneic blood transfusions.Key words: red blood cells, transfusion, single-unit, acute leukemia, hematopoietic stem cell transplantation. 2012;97(1)116-122. doi:10.3324/haematol.2011 This is an open-access paper. Citation: Berger MD, Gerber B, Arn K, Senn O, Schanz U, and Stussi G. Significant reduction of red blood cell transfusion requirements by changing from a double-unit to a single-unit transfusion policy in patients receiving intensive chemotherapy or stem cell transplantation. Haematologica

Implant-Based Breast Reconstruction Using a Titanium-Coated Polypropylene Mesh (TiLOOP Bra)

“…21 In retrospect, not all women in our collective were eligible for implant-based breast reconstruction using titanium-coated polypropylene mesh (Fig. Radiotherapy, an established risk factor for postoperative complications in implantbased breast reconstruction, was also not identified as a risk factor, most likely because of the low number of patients receiving radiotherapy (two TCPM, titanium-coated polypropylene mesh; LN, lymph nodes; SSM, skin-sparing mastectomy; NSM, nipple-sparing mastectomy; NSSM, no skin-sparing mastectomy; MRM, modified radical mastectomy.…”

“…[4][5][6] The additional advantages of these supportive interpositional materials are based on the reduced surgical time compared with autologous tissue reconstruction. 21 However, the indications for applying acellular dermal matrix or titaniumcoated polypropylene mesh differ considerably based on the surgeon's experience, the patient's skin condition, and the approval status of the device. The limitations are associated with higher risks for implant migration, malpositioning of the inframammary fold, and poor implant coverage at the lower lateral and inferior poles.…”

Assessing Iron Overload: Are We There Yet?

“…Reducing the number of red blood cell (RBC) transfusions may reduce nonrelapse mortality. A Swiss study in patients receiving intensive chemotherapy for hematologic malignancy and stem cell transplantation showed that a change from a double to single unit RBC transfusion policy is safe, sufficient to treat anemia, and associated with a reduction by 25% in RBC transfusion requirements and reduction in other complications associated with RBC transfusion (11). There was no evidence of more severe bleeding or more platelet transfusions during the single unit period, and the overall survival was similar in both single and double unit cohorts.…”

Single‐unit transfusions in the obstetric setting: a qualitative study

“…In one study, single-unit transfusion policy was associated with decreased RBC use without increases in bleeding or platelet transfusion. 26 Another demonstrated that increasing the number of RBC units transfused was associated with an increased risk of infection. 27 The Dutch WOMB trial, in which obstetric patients with acute anemia postpartum were randomized to receive either RBC transfusion (a median of 2 RBC units) or expectant management, was unable to demonstrate noninferiority in physical fatigue at 3 days postpartum with expectant management, although the difference was small.…”